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Preface
This issueofEnvironmentalHealthPerspectivesisthesecond
oftwovolumescomprising paperspresentedattheConference
on "Biomonitoring and Susceptibility Markers in Human
Cancer: Applications in Molecular Epidemiology and Risk
Assessment," which washeldOctober26throughNovember 1,
1991, inKailua-Kona, Hawaii. Thisconferencewasorganizedby
theInternational AgencyforResearchonCancer (IARC, Lyon,
France) andbytheNational CenterforToxicological Research/
FDA (NCTR, Jefferson, Arkansas, USA), andwasadditional-
ly sponsoredby theU.S. Environmental ProtectionAgency, the
CommissionoftheEuropeanCommunities, theHealthEffects
Institute, andthe U.S. National Cancer Institute.
Thefirstvolume focusesonbiomarkers ofsusceptibility and
includes papers on a) the relationship ofmolecular, chromo-
somal, andcellularsusceptibilitymarkersandthemultistagecar-
cinogenesis process inhumans; andb) theroleofgeneticpoly-
morphism of xenobiotic-metabolizing enzymes in cancer
susceptibility. The secondvolumedescribesa) recentprogress
in biomonitoring techniques and molecular dosimetry ap-
proachesandtheirapplicationtovariouspopulations exposedto
carcinogens; andb) issuesandimplications forusingbiomarkers
in cancer epidemiology and risk assessment.
Interestisincreasing inorganizingmultidisciplinary meetings
that bring together experimental oncologists, cancer epidemi-
ologists, geneticists, andclinicians toexplorethepotential ofin-
tegrated laboratory and field studies. Although one ofthe first
meetings ofthis kind was in 1972,' progress was slow in the
followingdecade, asavailableknowledgewastoolimitedtoallow
any recommendations useful forcancercontrol andprevention.
However, the concept ofcombined laboratory and epidemio-
logical studiesofhumancancerwasthenrecognizedandgained
support, as evidenced insubsequent2-5 conferences. This new
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approach has since been named metabolic, biochemical, or
molecular epidemiology.
Thislatestmeetingdiscussed recently developedmarkers for
use in molecular epidemiological studies for identifying sub-
populations and(hopefully) individuals athigherriskforcancer,
eitherbecausethey are morehighly exposed to carcinogens or
because inherited or acquired host factors render them more
susceptible. Fortheseindividuals, onceidentified, stepscanbe
takentominimizeexposure. Anoteofcaution, however, isneed-
ed whendiscussing genetic variations and susceptibility to en-
vironmentalagents. Itisessentialthatany scientific resultsthat
show an elevated, relative, or attributable risk associated with
any specificgenetic traitin relation tospecific exposureand to
disease outcome should have the most rigorous possible
methodological and theoretical basis. Otherwise, unethical or
undesirable useofsuchinformationwillprecludeanybeneficial
impact.
Wearepleasedthatanumberofepidemiologistsattendedthis
meeting incontrastto similarconferences wherethisdiscipline
was frequently underrepresented. In view of a) the pace of
developmentoftoolsfrommoleculardosimetry, molecularbio-
logy, andgenetics, asdescribed atthis meeting, andb) the fact
that many studies published under the label of molecular
epidemiologyhaveseriouslimitationsofepidemiological/statis-
ticaldesign(andshouldatbestbecalledlaboratoryinvestigations
onhuman subjects), thefield needs epidemiologists interested
indevelopingnewstrategiesfortheefficientdeploymentofthese
biomarkers.
We hope that the major advances presented at this meeting,
alongwiththeexcellentpresentationsandenthusiasmofthepar-
ticipants, will accelerate ongoing research in molecular and
biochemicalepidemiology. Inturn, this shouldsignificantly im-
provetheprocessofcancerriskassessmentandprevention and
protect thepublic health.
Finally, we are grateful to M. Anderson, X. Bosch, C.C.
Harris, R. Hayes, S.S. Hecht, P. Kleihues, J. Lewtas, A.
Likhachev, G. Lucier, F.P. Perera, R.J. Scheuplein, D. Shuker,
A. Sivak, S.R. Tannenbaum, P. Vineis, C.P. Wild, and H.
Yamasaki, who spentconsiderable time in helping to establish
theobjectives ofthis symposium andassembling theprogram.
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